ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2026
Real-world impact of mepolizumab on symptom control and health utility in severe chronic rhinosinusitis with nasal polyps: the RINOSUR 2.0 multicenter cohort study.
Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the real-world effectiveness of mepolizumab in patients with severe,uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), assessing its impacton sinonasal symptoms, endoscopic findings, asthma control, systemic corticosteroiduse, and quality of life (QoL) over 12 months.
methodsRINOSUR 2.0 was a prospective multicenter cohort study conducted in southernSpain. Ninety-six adult patients with severe, uncontrolled bilateral CRSwNP receivedmepolizumab as add-on therapy and were followed for 12 months. Outcomes wereassessed at baseline, 6, and 12 months. Primary endpoints included the 22-itemSinonasal Outcome Test (SNOT-22), visual analogue scale (VAS) symptom scores,and Nasal Polyp Score (NPS). Asthma control was evaluated using the Asthma ControlTest (ACT). Health utility was derived from SNOT-22 using a validated mappingalgorithm to estimate quality-adjusted life years (QALYs).
resultsMean SNOT-22 improved from 65.2 + 19.9 at baseline to 29.9 + 19.7 at 12 months(change -35.3; p<0.001), with 86.5% achieving the minimal clinically importantdifference. NPS decreased from 5.5 + 1.7 to 2.5 + 1.7 (p<0.001). ACT increased from17.1 + 5.4 to 23.4 + 3.4 (p<0.001). Health utility improved from 0.431 + 0.135 to 0.671+ 0.134, corresponding to a gain of 0.14 QALYs in the first year. Systemiccorticosteroid exposure was significantly reduced (p<0.001). Clinical improvement wasindependent of prior surgical extent after adjustment for baseline severity. Treatmentwas well tolerated.
conclusionIn routine practice, mepolizumab provides sustained improvements in QoL, endoscopicpolyp burden, and asthma control in severe CRSwNP, translating into clinicallymeaningful health utility gains.
Indexed as
Identifiers
42228110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.